Capricor Therapeutics Inc. stocks have been trading up by 14.26 percent following highly positive news driving investor optimism
Click Here for a Millionaire's POV on Trading CAPR
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways Traders Need To Know
- Shares of CAPR ripped roughly 80–100% in premarket trading after Q2 results and a positive FDA update on deramiocel, showing powerful event‑driven momentum.
- Cantor Fitzgerald upgraded Capricor Therapeutics to Overweight from Neutral and hiked its price target to $28 from $3.50, above the current analyst mean of $26.12.
- The FDA pushed the PDUFA decision for deramiocel to 2026/11/22 to review a major amendment built on 24‑month HOPE‑3 data focused on upper‑limb function.
- Capricor Therapeutics is pivoting its BLA toward a narrower upper‑limb indication after a 9–3 negative advisory vote on cardiomyopathy, with the FDA open to the revamped package.
- Activist Kaos Capital is pressing CAPR’s board for strategic changes, including new directors, an M&A and Strategic Alternatives Committee, and tighter cash discipline.
Live Update At 12:32:05 EDT: On Tuesday, August 25, 2026 Capricor Therapeutics Inc. stock [NASDAQ: CAPR] is trending up by 14.26%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
Capricor Therapeutics (CAPR) is trading like a textbook biotech momentum play. The daily chart shows a huge reset: the stock sat around $4 in early August, then launched into the $6–$8 zone as the FDA narrative and Q2 numbers hit. On 2026/08/25, CAPR closed at $7.76 after touching $8.60 intraday, holding most of its recent gains instead of giving them all back. That tells traders dip buyers are active.
Intraday, CAPR’s 5‑minute tape shows wide swings between roughly $7.70 and $8.30, with heavy liquidity around the open and into mid‑morning. That kind of range is a scalper’s playground but a swing trader’s risk if they chase late.
More Breaking News
- OKLO Stock Jumps As DOE Clears Groves Test Reactor
- TENX Stock Draws Bullish Targets Ahead Of Trial Data
- Bloom Energy Stock Jumps As AI Power Demand Fuels Breakout
- KEEL Stock Holds Support As Traders Map Next Move
Fundamentally, Capricor is still pre‑revenue. Q2 2026 numbers show zero sales and a net loss of about $40.7M, with operating cash burn near $31.5M and free cash flow around ‑$35.5M. Yet CAPR holds roughly $237.9M in cash and short‑term investments and sports a strong current ratio of 7.4, giving it at least 12 months of runway by management’s own guidance. Key returns like return on equity and return on assets are sharply negative, exactly what traders expect from a development‑stage biotech. The real driver here is not earnings; it is binary FDA risk on deramiocel.
Why Traders Are Watching CAPR’s FDA Timeline
CAPR has flipped from forgotten small‑cap biotech to front‑page momentum ticker in a matter of days. The catalyst chain is clear. First, Capricor reported Q2 2026 results: no revenue, widening losses, but a key win in the HOPE‑3 Phase 3 trial for deramiocel in Duchenne muscular dystrophy. The study hit its primary upper‑limb endpoint and even landed in The Lancet, giving CAPR serious scientific credibility.
At the same time, Capricor signaled a strategic pivot. After a 9–3 negative FDA advisory committee vote on the original cardiomyopathy indication, the company chose not to simply defend the old story. Instead, CAPR is amending its biologics license application to focus on upper‑limb function, backed by 24‑month HOPE‑3 extension data and more robust analyses.
The FDA responded by agreeing to review this major amendment and extend the PDUFA date from 2026/08/22 to 2026/11/22. For deramiocel, that keeps the regulatory door open. For CAPR traders, it defines the next hard catalyst. The market liked it: shares surged over 85% when the agency first agreed to review the amendment and rose again when the new November date was confirmed.
Layered on top of that, Cantor Fitzgerald jumped in with a high‑conviction view. The firm upgraded Capricor Therapeutics to Overweight from Neutral and jacked its price target to $28 from $3.50, well above the current mean target of $26.12. When a major shop multiplies its target eightfold right after Q2, traders notice. CAPR then ripped roughly 104% in premarket trading around that news flow, underscoring how tightly price is tied to each regulatory and analyst headline.
There is also a governance angle. Kaos Capital, a sizable shareholder, is pushing Capricor Therapeutics for board changes, an M&A and Strategic Alternatives Committee, and stronger cash preservation. That kind of activist pressure often precedes deal talk or strategic shifts, giving CAPR yet another potential catalyst beyond the FDA calendar.
Conclusion
For active traders, CAPR now sits at the intersection of science, regulation, and pure momentum. Capricor Therapeutics still has no product revenue and posts steep quarterly losses, but it also has around $237.9M in cash and short‑term investments and says it can fund operations for at least the next year without assuming deramiocel sales. The balance sheet buys Capricor time to see the FDA process through, yet the entire equity story still leans on that single DMD therapy.
The market’s message is clear: every new detail about the deramiocel BLA — especially the 2026/11/22 PDUFA date and the upper‑limb indication focus — will move CAPR sharply. Add in Cantor’s $28 target, the 80–100% premarket spikes, and activist Kaos Capital circling the boardroom, and CAPR becomes a high‑volatility classroom for traders who study news catalysts. For pattern‑recognition‑focused traders, this is where mindset matters: as Tim Bohen, lead trainer with StocksToTrade says, “There’s a pattern in everything; you just have to stick around long enough to see it.” That kind of patience in watching how CAPR trades around headlines, liquidity, and regulatory milestones can turn chaotic price action into a structured trading playbook.
This content is for educational and research purposes only, but the trading lesson is timeless. As Tim Sykes likes to say, “Volatility is opportunity for prepared traders, but it’s a disaster for gamblers.” Capricor Therapeutics is giving prepared traders a live case study in how fast sentiment can swing when Wall Street upgrades, FDA decisions, and activist pressure all collide on one ticker.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.